title: Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes.
abstract: A guanidine-based antibody avidity assay for the identification of recently acquired human immunodeficiency virus type 1 (HIV-1) infection was evaluated. The kinetics of maturation of antibody avidity were determined prospectively in 23 persons undergoing acute seroconversion followed for up to 1,075 days. Avidity indices (AI) of <or=0.75 and <or=0.80 reproducibly identified seroconversion within the previous 125 (95% confidence interval [CI], 85 to 164) and 142 (95% CI, 101 to 183) days, respectively. To validate the assay, 432 serum samples from newly diagnosed patients were tested by both the avidity assay and the detuned assay. Results were highly concordant (kappa value for agreement, 0.85). The avidity assay was subsequently used to screen 134 consecutive newly diagnosed patients, including 55/134 (41%) infected with non-B subtypes (A, C, D, G, CRF01, CRF02, CRF06, CRF13, and CRF16). In this cohort, 25/79 (32%) persons with the B subtype and 7/55 (13%) with non-B subtypes showed an AI of <or=0.75, and there were 16/25 (64%) and 3/7 (43%) persons, respectively, with a documented history of acute seroconversion illness within the predicted seroconversion interval. An AI of <or=0.75 was also observed for four patients (three with the B subtype and one with a non-B subtype) who presented with AIDS-defining conditions. In multivariate analysis, an AI of <or=0.75 was associated with younger age, higher HIV-1 plasma RNA load, and being born in the United Kingdom or Ireland rather than in Africa but not with gender, ethnicity, risk group, HIV-1 subtype, or CD4 counts. In conclusion, HIV antibody avidity testing provides a reliable method for identifying recently acquired HIV-1 infection. Results are affected by advanced disease and should therefore be interpreted in the context of other clinical parameters.
authors.affiliation: Department of Virology, Royal Free Hospital, Royal Free and University College Medical School, London, UK.
authors.forename: A
authors.initials: A
authors.lastname: Chawla
authors.forename: G
authors.initials: G
authors.lastname: Murphy
authors.forename: C
authors.initials: C
authors.lastname: Donnelly
authors.forename: C L
authors.initials: CL
authors.lastname: Booth
authors.forename: M
authors.initials: M
authors.lastname: Johnson
authors.forename: J V
authors.initials: JV
authors.lastname: Parry
authors.forename: A
authors.initials: A
authors.lastname: Phillips
authors.forename: A M
authors.initials: AM
authors.lastname: Geretti
mesh_terms: D000328:Adult; D000368:Aged; D000915:Antibody Affinity; D005260:Female; D019791:Guanidine; D015483:HIV Antibodies / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology / Q000503:physiopathology / Q000821:virology; D006679:HIV Seropositivity / Q000276:immunology*; D015497:HIV-1 / Q000145:classification* / Q000276:immunology*; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis
chemical_list: D015483:HIV Antibodies; D019791:Guanidine